Skip to main content

Table 3 Meta-analysis results using reported multivariable adjusted data

From: Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis

Analysis for adjusted mortality data Studies (N) Adjusted HR (95% CI)
Totally high-risk patient populations 5 4.67 (2.18, 9.99); I2 = 77.7%
 Low risk of bias 4 4.62 (1.87, 11.42); I2 = 83.3%
 CS infection comparator 2 2.07 (1.22, 3.53); I2 = 0.0%
 No CR infection comparator 2 8.63 (4.12, 18.08); I2 = 31.6%
 No infection comparator 1 6.92 (3.24, 14.79)
 Longer-term (> 30 days) mortality 4 6.67 (3.88, 11.49); I2 = 0.0%
 Italy 2 4.53 (0.78, 26.20); I2 = 93.3%
 USA 3 5.19 (2.99, 9.01); I2 = 0.0%
Partially and totally high-risk patient populations 8 3.38 (1.93, 5.94); I2 = 76.0%
 Low risk of bias 6 3.87 (2.10, 7.13); I2 = 76.9%
 CS infection comparator 4 1.93 (1.24, 2.99); I2 = 8.2%
 No CR infection comparator 2 8.63 (4.12, 18.08); I2 = 31.6%
 No infection comparator 2 4.08 (1.56, 10.65); I2 = 76.5%
 In-hospital/≤30-day mortality 4 2.05 (1.39, 3.02); I2 = 16.9%
 Longer-term (> 30 days) mortality 4 6.67 (3.88, 11.49); I2 = 36.6%
 CRKP studies only 7 3.45 (1.83, 6.51); I2 = 79.3%
 Studies reporting HR 6 4.17 (2.23, 7.80); I2 = 76.6%
 Studies reporting OR 2 1.71 (0.60, 4.82); I2 = 60.1%
 Italy 2 4.53 (0.78, 26.20); I2 = 93.3%
 USA 6 3.02 (1.79, 5.08); I2 = 54.2%
  1. CI Confidence interval, CRKP Carbapenem-resistant Klebsiella pneumoniae, CS Carbapenem-susceptible, HR Hazard ratio, N Number, OR Odds ratio
\